最新一期业绩显示，2025年一季报，公司实现营业收入4.20亿元，同比-5.25%；净利润6508.82万元，同 比68.98%，销售毛利率58.34%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)75理邦仪器35.8841.763.2767.70亿行业平均 48.1145.994.51102.53亿行业中值35.8836.472.2646.14亿1天益医疗-1660.65-2844.501.7721.16亿2澳华内 镜-568.12284.944.5559.87亿3诺唯赞-410.18-485.142.2587.78亿4博晖创新-322.37511.563.4447.30亿5爱朋 医疗-299.71227.693.6124.59亿6硕世生物-125.29-1830.871.1236.65亿7奥精医疗-116.13-170.211.5321.55亿 8睿昂基因-94.34-77.451.3412.21亿9康泰医学-83.02-70.152.9654.65亿10中红医疗-66.39-52.950.8446.14亿 11华大智造-62.30-55.294.29332.17亿 来源：金融界 4月30日， ...

4月30日，泰山石油今日收盘5.98元，下跌1.64%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到21.50倍，总市值28.75亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)14泰山石油21.5028.952.6328.75亿行业平均 12.6011.231.151665.30亿行业中值25.3728.991.5252.42亿1沈阳化工-24.94-17.612.0929.58亿2茂化实 华-24.30-21.702.9518.09亿3中晟高科-18.46-12.406.8921.11亿4博汇股份-8.18-6.806.2020.87亿5国际实 业-5.73-5.731.2425.14亿6华锦股份-3.20-3.020.7684.45亿7*ST海越-2.01-2.170.256.51亿8中国海油 8.828.621.5211891.99亿9中国石油8.828.880.9314623.38亿10ST新潮9.208.411.01218.30亿11广汇能源 13.3512.841.37380.16亿 来源：金融界 中国石化山东泰山石油股份有限公司的主营业务为成品油批发零售业务以及非 ...

Group 1 - The core viewpoint of the articles highlights Huamao Logistics' current market performance, including a closing price of 6.28 yuan and a decline of 3.09%, with a rolling PE ratio of 16.78 times and a total market value of 8.221 billion yuan [1] - The logistics industry has an average PE ratio of 23.63 times and a median of 20.92 times, positioning Huamao Logistics at the 26th rank within the industry [1] - As of the first quarter of 2025, seven institutions hold shares in Huamao Logistics, with a total holding of 658.1514 million shares valued at 3.745 billion yuan [1] Group 2 - Huamao Logistics specializes in third-party international comprehensive logistics and international logistics solutions, offering services such as comprehensive logistics, international air and sea freight, cross-border e-commerce logistics, special logistics, and third-party warehousing [1] - The company ranks 16th in the latest global shipping and air freight forwarder list published by Transport Topics, indicating its competitive position in the international logistics market [1] - For the first quarter of 2025, Huamao Logistics reported an operating revenue of 3.992 billion yuan, a year-on-year increase of 2.82%, and a net profit of 118 million yuan, reflecting a year-on-year decrease of 29.42%, with a sales gross margin of 11.39% [1]

Group 1 - The core business of the company is the research, production, and sales of mid-to-high-end CNC machine tools, including large machining centers, vertical CNC machine tools, and horizontal CNC machine tools [2] - As of March 31, 2025, the company had 11,793 shareholders, a decrease of 431 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company achieved a revenue of 569 million yuan in the first quarter of 2025, representing a year-on-year increase of 3.80%, while net profit was 61.36 million yuan, a year-on-year decrease of 11.78%, with a gross profit margin of 21.11% [2] Group 2 - The company's current price-to-earnings (PE) ratio is 19.84, compared to the industry average of 75.41 and the industry median of 38.33, ranking 68th in the industry [1][3] - The company has received multiple honors, including recognition as a Jiangsu Province Intelligent Manufacturing Factory and a Jiangsu Province Five-Star Cloud Enterprise, among others [2] - The company has been awarded the CNAS certificate for its testing laboratory, indicating compliance with national standards [2]

4月29日，万邦德今日收盘5.81元，上涨1.40%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到64.63倍，总市值35.83亿元。 从行业市盈率排名来看，公司所处的化学制药行业市盈率平均45.68倍，行业中值26.55倍，万邦德排名 第119位。 万邦德医药控股集团股份有限公司主营业务为现代中药、化学原料药及化学制剂的研发、生产和销售以 及提供高端医疗器械研制、医疗设备服务和提供医院工程服务。主要产品是心脑血管系统主导产品、神 经系统主导产品、呼吸系统主导产品、消化系统主导产品、精神系统主导产品、骨科植入器械、医疗设 备及医院工程服务、一次性无菌医用高分子耗材、防护用品。 最新一期业绩显示，2024年年报，公司实现营业收入14.43亿元，同比-6.39%；净利润5544.10万元，同 比12.66%，销售毛利率41.83%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)119万邦德64.6364.631.3435.83亿行业平均 45.6845.545.50119.08亿行业中值26.5527.442.1948.23亿1上海谊众-1095.821259.436.1787.85亿2 ...

Group 1 - The core viewpoint of the article highlights Chengdu Xian Dao's stock performance, with a closing price of 14.88 yuan, up 5.08%, and a rolling PE ratio of 90.75, marking a new low in 17 days, with a total market value of 5.962 billion yuan [1] - Chengdu Xian Dao ranks 37th in the medical services industry, which has an average PE ratio of 40.74 and a median of 42.36 [1] - As of March 31, 2025, the number of shareholders for Chengdu Xian Dao increased to 16,254, with an average holding value of 352,800 yuan and an average holding of 27,600 shares [1] Group 2 - Chengdu Xian Dao specializes in drug discovery and development services related to DEL technology, including DEL screening services, custom DEL libraries, FBDD/SBDD, custom drug development, compound structure intellectual property transfer, and other related services [1] - In the latest quarterly report for Q1 2025, the company reported revenue of 107 million yuan, a year-on-year decrease of 0.60%, while net profit reached 28.2844 million yuan, a year-on-year increase of 102.90%, with a gross profit margin of 51.87% [1]

Group 1 - The core viewpoint of the article highlights that Chunzhi Medical's stock closed at 14.28 yuan, down 3.32%, with a rolling PE ratio of 43.82 times and a total market value of 5.477 billion yuan [1] - The average PE ratio for the medical device industry is 46.40 times, with a median of 34.81 times, placing Chunzhi Medical at the 85th position in the industry ranking [1] - As of the 2024 annual report, four institutions hold shares in Chunzhi Medical, with a total of 382,700 shares valued at 0.05 million yuan [1] Group 2 - Chunzhi Medical specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, and PRP preparation kits [1] - The latest performance report for 2024 shows that the company achieved operating revenue of 806 million yuan, a year-on-year decrease of 33.32%, and a net profit of 125 million yuan, down 55.01%, with a gross profit margin of 66.63% [1]

Group 1 - The core viewpoint of the article highlights the financial performance and market position of Aibo Medical, indicating a decline in stock price and a comparison with industry averages [1] - Aibo Medical's closing stock price is 79.25 yuan, down 2.92%, with a rolling PE ratio of 39.73 times and a total market capitalization of 15.021 billion yuan [1] - The average PE ratio for the medical device industry is 46.40 times, with a median of 34.81 times, placing Aibo Medical at the 82nd position in the industry ranking [1] Group 2 - As of the first quarter of 2025, 67 institutions hold shares in Aibo Medical, including 62 funds, with a total shareholding of 67.74 million shares valued at 6.637 billion yuan [1] - Aibo Medical specializes in the research, development, production, sales, and related services of ophthalmic medical devices, with key products including artificial lenses and other vision care products [1] - The latest financial results for the first quarter of 2025 show Aibo Medical achieving a revenue of 357 million yuan, a year-on-year increase of 15.07%, while net profit was 92.558 million yuan, reflecting a year-on-year decrease of 10.05%, with a gross profit margin of 64.60% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Lehui International, which has a high PE ratio compared to its industry peers [1][2] - As of April 28, Lehui International's closing price was 22.4 yuan, with a PE ratio of 101.61 times, significantly higher than the industry average of 60.85 times and the median of 45.87 times [1][2] - The company's total market capitalization is 2.704 billion yuan, ranking it 220th in the industry [1][2] Group 2 - Lehui International specializes in the research, production, and manufacturing of liquid food equipment, with key products including brewing equipment and sterile filling equipment [1] - The company has been recognized as a national champion in manufacturing, with its beer brewing equipment and filtration equipment awarded national-level champion products [1] - In the first quarter of 2025, Lehui International reported a revenue of 206 million yuan, a year-on-year decrease of 5.87%, while net profit reached 8.9383 million yuan, showing a significant increase of 160.61% [1]

Group 1 - The core viewpoint of the news is that WuXi AppTec's stock price has reached a new low in 17 days, with a closing price of 58.09 yuan and a rolling PE ratio of 17.75 times, significantly lower than the industry average [1] - As of the first quarter of 2025, a total of 383 institutions hold shares in WuXi AppTec, with 378 being funds, totaling 1,109,788,100 shares and a market value of 74.711 billion yuan [1] - WuXi AppTec's main business is providing integrated, end-to-end drug research and development services for the global pharmaceutical and life sciences industry, with key products including chemical, testing, and biological services [1] Group 2 - In the first quarter of 2025, WuXi AppTec reported a revenue of 9.655 billion yuan, representing a year-on-year increase of 20.96%, and a net profit of 3.672 billion yuan, reflecting a year-on-year increase of 89.06%, with a gross profit margin of 42.26% [1] - The average PE ratio for the medical services industry is 40.74 times, with a median of 42.36 times, placing WuXi AppTec at the 17th position in the industry ranking [2] - The total market capitalization of WuXi AppTec is 167.763 billion yuan [2]